

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Estimated average burden
 hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Puttagunta Sailaja <small>(Last) (First) (Middle)</small> C/O ITERUM THERAPEUTICS PLC, FITZWILLIAM COURT, FL. 1, LEESON CLOSE <small>(Street)</small> DUBLIN 2, L2 <small>(City) (State) (Zip)</small>	2. Issuer Name and Ticker or Trading Symbol Iterum Therapeutics plc [ITRM]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) ___ Director ___ 10% Owner ___ Officer (give title below) ___ Other (specify below) Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year) 12/10/2021		6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned		

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Share Option (Right to Buy)	\$ 0.48	12/10/2021		A		1,800,000		(1)	12/09/2031	Ordinary Shares	1,800,000	\$ 0	1,800,000	D	
Restricted Share Units	(2)	12/10/2021		A		500,000		(3)	(3)	Ordinary Shares	500,000	\$ 0	500,000	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Puttagunta Sailaja C/O ITERUM THERAPEUTICS PLC FITZWILLIAM COURT, FL. 1, LEESON CLOSE DUBLIN 2, L2			Chief Medical Officer	

Signatures

/s/ Sailaja Puttagunta	12/14/2021
<small>Signature of Reporting Person</small>	<small>Date</small>

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares underlying this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of December 1, 2021 and the remaining 75% will vest in equal monthly installments thereafter until December 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date.
- (2) Each restricted share unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU.

Subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date and the other terms and conditions of the Issuer's 2021 Inducement Equity Incentive Plan, (3) the RSUs shall vest over four years with 25% of the RSUs vesting on each one-year anniversary of December 1, 2021, such that the total number of RSUs shall be fully vested by December 1, 2025.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.